PLCRC biedt een platform voor het verzamelen van

gegevens van patiënten met dikkedarmkanker.

 

deelnemende
centra

 

deelnemende
patiënten

PLCRC-QUALITAS: QUAlity of LIfe in meTAStatic colorectal cancer patients treated with trifluridine-tipiracil in late line in the PLCRC cohort

23 juni 2018

One of the most recent treatment options for metastatic colorectal cancer is trifluridine tipiracil (= TAS-102 = Lonsurf®). This is a combination tablet of two medicines that together prevent the growth of tumor cells. Previous research has shown that trifluridine tipiracil is effective in the treatment of colorectal cancer: treated patients live on average 1.8 months longer than patients who do not receive trifluridine tipiracil. Since February 2017, trifluridine tipiracil is available in the Netherlands. Only patients who are unresponsive to or intolerant to standard therapies are eligible for treatment with trifluridine tipiracil.

Lees meer

MEDOCC: molecular Early Detection of Colon Cancer

22 juli 2016

The incidence of large bowel cancer is increasing. A staging system is used to indicate severity of disease, in which stage 1 until 3 comprise a group of patients without metastases to other organs. These stages of large bowel cancer can be curatively treated with surgery by resecting the tumor and involved lymph nodes.

Read more

The PLCRC- SPECTRE study: Ultra high field 7.0 Tesla MR SPECTRoscopy to monitor capecitabinE metabolism in liver metastases: a proof of concept study

3 augustus 2016

Capecitabine, an oral prodrug of 5-flouroracil (5FU), is the most widely used chemotherapeutic agent in the treatment of metastatic colorectal cancer. Response evaluation takes place nine weeks after start of treatment. This results in unnecessary toxicity and costs for non-responding patients, emphasizing the need to identify new markers that predict treatment response in early stage.

Read more

Research on the outcomes of patients with rectal cancer

5 februari 2016

Every year, over 4,300 people in the Netherlands are diagnosed with rectal cancer, and more than 1,000 patients die from this disease. Treatment of rectal cancer consists of surgery, usually preceded by radiotherapy with or without chemotherapy. This treatment is associated with a substantial risk of short- and longterm side effects. Research into more effective treatment with fewer side effects is therefore of great importance.

Read more

Improving clinical management of colon cancer through CONNECTION, a nation-wide Colon Cancer Registry and Stratification effort.

17 november 2015

Colorectal cancer is still a devastating disease with over 600.000 deaths per year worldwide. This is in part due to poor survival of patients with late stage disease where curative treatment options are limited, but even at stage II around 20% of the patients will develop a recurrence despite effective surgical resection of the primary tumor. Identification of these stage II patients at risk and optimization of the therapy provided is therefore an important goal to improve outcome in colon cancer.

Read more

‘’Specialized nutrition to improve Clinical Outcomes in colorectal cancer PatiEnts (SCOPE)’’ project

9 november 2015

Approximately 15,000 patients per year are diagnosed with colorectal cancer (CRC) in the Netherlands. Treatment can consist of surgery, often complemented with radiation or systemic therapy. Patients with colorectal cancer often perceive weight loss, reduced muscle mass, fatigue and loss of appetite as a result of their disease and treatments. It is currently assumed that maintaining muscle mass and a well-balanced nutritional status after diagnosis contributes to the success of treatment.

Read more